乐观
$24.00
情景价格
$11.370
+0.230 (+2.02%)收盘时
Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.
Cellebrite DI Ltd is not a strong buy right now due to its current price of $11.03, which is significantly below the average analyst price target of $20. However, the stock has shown a 21% year-over-year growth in annual recurring revenue, indicating potential for recovery. The main risk is the recent earnings miss with an EPS surprise of -44.44%, suggesting that the company's financial performance may not meet investor expectations in the near term.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Cellebrite to Report Q3 2026 Financial Results on November 12

Cellebrite to Release Q3 2026 Financial Results on November 12

Cellebrite to Release Q3 2026 Financial Results

Cellebrite to Release Q3 2026 Financial Results on November 12

Stocks Investors Should Consider Selling Now
Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. It operates in the Technology sector.
Cellebrite DI Ltd is not a strong buy right now due to its current price of $11.03, which is significantly below the average analyst price target of $20. However, the stock has shown a 21% year-over-year growth in annual recurring revenue, indicating potential for recovery. The main risk is the recent earnings miss with an EPS surprise of -44.44%, suggesting that the company's financial performance may not meet investor expectations in the near term.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。